EW’s stock price forecast this week factors in resilience in cardiovascular product sales, with consensus EPS revisions moving +3% higher. This uptick aligns with broader healthcare sector strength reflected in the S&P Healthcare Index. Next, on comparing Edwards Lifesciences' net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 12% over the last few years. We just received data on a new analyst forecast for $EW. Rick Wise from Stifel set a price target of 85.0 for EW. With the Fed’s current interest rate stance stabilizing valuations, EW forecasts benefit from lower discount rate pressures, supporting an average 12-month target of $98 per share by major investment banks.